HLA-C and neoplasm: In contrast to TCR-engineered T cells, CAR-T cells recognize tumor antigens with an MHC-independent pattern, directly identifying and combining targeting surface molecules expressed on tumor cells.242 Although successful in multiple hematopoietic malignancies, the benefit of CAR-T cells in solid tumors has not been forthcoming.243–245